Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma

Autor: Rozeman, E. A., Hoefsmit, E. P., Reijers, I. L. M., Saw, R. P. M., Versluis, J. M., Krijgsman, O., Dimitriadis, P., Sikorska, K., van de Wiel, B. A., Eriksson, H., Gonzalez, M., Torres Acosta, A., Grijpink-Ongering, L. G., Shannon, K., Haanen, J. B. A. G., Stretch, J., Ch’ng, S., Nieweg, O. E., Mallo, H. A., Adriaansz, S., Kerkhoven, R. M., Cornelissen, S., Broeks, A., Klop, W. M. C., Zuur, C. L., van Houdt, W. J., Peeper, D. S., Spillane, A. J., van Akkooi, A. C. J., Scolyer, R. A., Schumacher, T. N. M., Menzies, A. M., Long, G. V., Blank, C. U.
Zdroj: Nature Medicine; February 2021, Vol. 27 Issue: 2 p256-263, 8p
Abstrakt: Neoadjuvant ipilimumab plus nivolumab showed high pathologic response rates (pRRs) in patients with macroscopic stage III melanoma in the phase 1b OpACIN (NCT02437279) and phase 2 OpACIN-neo (NCT02977052) studies1,2. While the results are promising, data on the durability of these pathologic responses and baseline biomarkers for response and survival were lacking. After a median follow-up of 4 years, none of the patients with a pathologic response (n?=?7/9 patients) in the OpACIN study had relapsed. In OpACIN-neo (n?=?86), the 2-year estimated relapse-free survival was 84% for all patients, 97% for patients achieving a pathologic response and 36% for nonresponders (P?
Databáze: Supplemental Index
Externí odkaz: